19. Has any other disease or condition including psychiatric conditions at Screening or at Randomization that, in the opinion of the investigator, may adversely affect his or her participation in the study either by being a safety risk to the subject, affecting any of the pharmacokinetic or pharmacodynamic measurements, or making it difficult to successfully manage and follow the subject according to the protocol.